Sign up to save your podcasts
Or
Share Generic Competition for Dimethyl Fumarate
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Generic Competition for Dimethyl Fumarate
Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the full article at 46brooklyn.com.
To hear the full podcast: https://www.neurology.org/podcast
View all episodes
By American Academy of Neurology
4.8
132132 ratings
Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the full article at 46brooklyn.com.
To hear the full podcast: https://www.neurology.org/podcast
More shows like Neurology Minute
View all
NEJM This Week
321 Listeners
JAMA Clinical Reviews
504 Listeners
Neurology® Podcast
299 Listeners
Practical Neurology Podcast
53 Listeners
Mayo Clinic Talks
298 Listeners
The Curbsiders Internal Medicine Podcast
3,374 Listeners
JAMA Neurology Author Interviews
16 Listeners
Core IM | Internal Medicine Podcast
1,150 Listeners
Neurology Today in 5
24 Listeners
Annals On Call Podcast
194 Listeners
JAMA Medical News
94 Listeners
The Clinical Problem Solvers
518 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
367 Listeners
Neurology Exam Prep Podcast
189 Listeners
Continuum Audio
80 Listeners